IDHIFA (enasidenib)
SELF ADMINISTRATION
Indications for Prior Authorization:
- Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase-2 (IDH2) positive mutation as detected by an FDA-approved test
All of the following must be met as a condition for coverage:
- Prescribed by an oncologist, AND
- Patient is 18 years or older, AND
- Confirmed presence of IDH2 mutations in the blood or bone marrow
Dosing:
- 100 mg orally once daily
Approval:
- 1 year
Last review date: September 4, 2018